The liver is where most of the body supply of plasmalogens is made, so it is a fair question whether liver disease changes plasmalogen status, and whether plasmalogen status says anything useful about liver disease. Two human studies have now looked, one in serum lipoproteins and one directly in liver tissue, and both find plasmalogens showing up in the difference between a fatty liver and an inflamed one. A third study, in mice, went further and gave plasmalogens as a treatment. Keeping those apart matters, because only one of the three is about intervention and it is the one that was not done in people. This is a summary of measurements, not advice; liver disease is managed by a clinician.
Key Takeaways
- Plasmalogen synthesis starts in the peroxisome and finishes in the endoplasmic reticulum, and the liver is a principal site, which is the mechanistic reason liver disease is expected to interact with plasmalogen status at all.
- In patients with non-alcoholic steatohepatitis, the plasmalogen to phospholipid ratio was significantly lower than in healthy volunteers across every lipoprotein fraction measured, not just one.
- A 2026 study of liver tissue from 106 patients with severe obesity found 45 metabolites separating simple steatosis from steatohepatitis, and two ethanolamine plasmalogen species were among the eight that replicated in the validation cohort.
- A 2021 study reporting that plasmalogen administration reduced hepatic steatosis was done in mice. It is a mechanism result in an animal model and is not evidence that a supplement does this in people.
- No human trial has tested a plasmalogen supplement for fatty liver disease. The human data here is associative and diagnostic in character, not therapeutic.
Why the Liver Is the Obvious Place to Look
Plasmalogen assembly is a two-organelle job. The first steps happen inside peroxisomes and the molecule is finished in the endoplasmic reticulum, a sequence set out in our article on the peroxisomal synthesis pathway, with the broader picture in how the body makes plasmalogens. Because hepatocytes are peroxisome-rich and the liver exports lipids to the rest of the body in lipoproteins, a liver under metabolic stress is a plausible place for plasmalogen production and distribution to change. That is a reason to look, not a finding in itself.
What the Serum Lipoprotein Study Found in NASH Patients
A 2019 study separated serum lipoproteins by gel-filtration chromatography from patients with non-alcoholic steatohepatitis and from healthy volunteers, then quantified ethanolamine and choline plasmalogens by liquid chromatography mass spectrometry. Two results came out of it. First, plasmalogen levels were higher in HDL than in VLDL or LDL in both groups, which tells you which particle carries most of the circulating pool. Second, the ratio of plasmalogens to total phospholipid was significantly lower in the NASH patients than in controls, and lower in every lipoprotein fraction rather than in one[1].
The authors also ran an oxidation experiment on LDL taken from healthy serum and found both plasmalogen classes fell during the early stages of oxidation, before other markers moved. That is the basis for their suggestion that plasmalogens could serve as an early-oxidation biomarker in NASH. It is a proposal about diagnosis, and it has not been validated as a clinical test.
The 2026 Liver Tissue Study
A more recent study went to the tissue itself. Non-targeted metabolomics was run on liver samples from 106 Finnish patients with severe obesity, with a separate validation cohort, asking which metabolites distinguish simple steatosis from metabolic dysfunction-associated steatohepatitis. Forty-five metabolites differed between the two groups. Of the twenty carried forward, eight replicated in the validation cohort, and two of those eight were ethanolamine plasmalogen species: 1-(1-enyl-palmitoyl)-2-arachidonoyl-GPE, written P-16:0/20:4, and 1-(1-enyl-stearoyl)-2-arachidonoyl-GPE, written P-18:0/20:4[2].
Two points keep this in proportion. Plasmalogens were not the headline of that study; they were two entries in a list that also included n-acetylneuraminate and several unrelated metabolites, and the paper is about progression signatures rather than about ether lipids. And the design is cross-sectional, so it identifies metabolites that differ between disease stages, not metabolites that drive the transition between them.
The Mouse Study, Labelled as Such
A 2021 paper is the one most likely to be quoted out of context, so it is worth stating its species in the same breath as its result. Working in mice, the authors reported that peroxisome dysfunction and impaired ethanolamine plasmalogen synthesis occurred in both liver and hippocampus in two mouse models, that knocking down GNPAT in hepatocytes to induce plasmalogen deficiency raised p75NTR and reduced lipolysis and thereby worsened steatosis, and that administering ethanolamine plasmalogen improved steatosis and memory measures through restoration of a TrkA to p75NTR balance[3].
That is a coherent mechanistic story and it is the only one of the three studies here that actually gave plasmalogens to anything. It is also entirely in mice. No effect size from that paper transfers to a human dose, a human liver, or a human outcome, and the step from a mouse mechanism to a human therapy is exactly the step that fails most often in metabolic disease. Treating it as support for supplementation in people would be reading it as something it is not.
What Someone With Fatty Liver Should Take From This
The honest position is that plasmalogens look like a real part of the lipid signature of fatty liver disease in humans, and that nobody has tested whether changing them changes anything. There is no human trial of plasmalogen supplementation for MASLD or MASH: not for liver fat, not for liver enzymes, not for fibrosis, not for progression. Anyone with diagnosed liver disease also has a specific reason to check before adding a supplement, since the liver is the organ processing it, and that check belongs with a hepatologist or the physician managing the condition.
What the research does support is a more modest claim: the liver and plasmalogen status are metabolically linked in ways that show up consistently in measurement, and the link runs in both directions, since the liver both makes plasmalogens and exports them. Readers interested in the circulating side of that picture may find our article on plasmalogens and cardiovascular health relevant, since it deals with the same lipoprotein fractions measured here.
Frequently Asked Questions
Are plasmalogens lower in people with fatty liver disease?
In the human data available, yes. A 2019 study found the plasmalogen to phospholipid ratio was significantly lower in patients with non-alcoholic steatohepatitis than in healthy volunteers, across every lipoprotein fraction measured. A 2026 study of liver tissue from 106 patients found two ethanolamine plasmalogen species among the metabolites separating steatosis from steatohepatitis.
Has a plasmalogen supplement been shown to improve fatty liver?
Not in people. The study reporting that plasmalogen administration reduced hepatic steatosis was done in mice. No human trial has tested plasmalogen supplementation for MASLD or MASH, for liver fat, liver enzymes, fibrosis or progression.
Why would the liver matter for plasmalogen levels?
Plasmalogen synthesis begins in peroxisomes and finishes in the endoplasmic reticulum, and the liver is a principal site of production as well as the organ that exports lipids in lipoproteins. That is why liver disease is expected to interact with plasmalogen status, though the direction and clinical meaning of that interaction are still being worked out.
References
- Ikuta A, Sakurai T, Nishimukai M, Takahashi Y, Nagasaka A, Hui SP, Hara H, Chiba H. Composition of plasmalogens in serum lipoproteins from patients with non-alcoholic steatohepatitis and their susceptibility to oxidation. Clinica Chimica Acta (2019). PMID 30796899
- Palomurto S, Flam E, Kaminska D, et al. Liver Metabolomic Profiling Reveals Distinct Signatures Between Steatosis and Metabolic Dysfunction-Associated Steatohepatitis. Liver International (2026). PMID 41684045
- Liu Y, Cong P, Zhang T, et al. Plasmalogen attenuates the development of hepatic steatosis and cognitive deficit through mechanism involving p75NTR inhibition. Redox Biology (2021). Mouse study. PMID 33984602
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
